Abstract
Cobra Venom Factor (CVF) is the complement-activating protein in cobra venom. CVF is a structural and functional analog of complement component C3. In serum, CVF forms a physicochemically stable and control-resistant C3/C5 convertase that continuously activates C3 and C5, ultimately leading to depletion of serum complement. As CVF can be safely administered to vertebrate animals, it has become an important tool for complement depletion to study the biological functions of complement and its role in the pathogenesis of disease. CVF has also been used for targeted complement activation by chemically coupling it to monoclonal antibodies. Complement depletion is an attractive concept for pharmacological intervention in diseases where complement activation is part of the pathogenetic mechanism. Toward that end, the structural homology of CVF and C3 has been exploited by creating hybrid proteins in which short portions of C3 sequence have been exchanged with corresponding portions of CVF that introduce the desired ability of forming a stable convertase into human C3. These human C3 derivatives are “humanized CVF” proteins that represent an attractive biopharmaceutical for therapeutic complement depletion.
Keywords: Cobra Venom Factor, CVF, complement, complement system, complement depletion, complement inhibition, alternative pathway, C3 convertase, protein humanization
Current Pharmaceutical Design
Title: Humanized Cobra Venom Factor: Experimental Therapeutics for Targeted Complement Activation and Complement Depletion
Volume: 13 Issue: 28
Author(s): Carl-Wilhelm Vogel and David C. Fritzinger
Affiliation:
Keywords: Cobra Venom Factor, CVF, complement, complement system, complement depletion, complement inhibition, alternative pathway, C3 convertase, protein humanization
Abstract: Cobra Venom Factor (CVF) is the complement-activating protein in cobra venom. CVF is a structural and functional analog of complement component C3. In serum, CVF forms a physicochemically stable and control-resistant C3/C5 convertase that continuously activates C3 and C5, ultimately leading to depletion of serum complement. As CVF can be safely administered to vertebrate animals, it has become an important tool for complement depletion to study the biological functions of complement and its role in the pathogenesis of disease. CVF has also been used for targeted complement activation by chemically coupling it to monoclonal antibodies. Complement depletion is an attractive concept for pharmacological intervention in diseases where complement activation is part of the pathogenetic mechanism. Toward that end, the structural homology of CVF and C3 has been exploited by creating hybrid proteins in which short portions of C3 sequence have been exchanged with corresponding portions of CVF that introduce the desired ability of forming a stable convertase into human C3. These human C3 derivatives are “humanized CVF” proteins that represent an attractive biopharmaceutical for therapeutic complement depletion.
Export Options
About this article
Cite this article as:
Vogel Carl-Wilhelm and Fritzinger C. David, Humanized Cobra Venom Factor: Experimental Therapeutics for Targeted Complement Activation and Complement Depletion, Current Pharmaceutical Design 2007; 13 (28) . https://dx.doi.org/10.2174/138161207782023748
DOI https://dx.doi.org/10.2174/138161207782023748 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design, Synthesis and Evaluation of Chalcone Derivatives as Anti- Inflammatory, Antioxidant and Antiulcer Agents
Letters in Drug Design & Discovery Role of Molecular Hydrogen in Skin Diseases and its Impact in Beauty
Current Pharmaceutical Design Vascular Endothelial Growth Factor and Angiopoietins in Neurovascular Regeneration and Protection Following Stroke
Current Neurovascular Research Role of Netrin-1 Beyond the Brain: From Biomarker of Tissue Injury to Therapy for Inflammatory Diseases
Recent Patents on Biomarkers The Vascular Endothelin System in Hypertension - Recent Patents and Discoveries
Recent Patents on Cardiovascular Drug Discovery D-Galactose as a Vector for Prodrug Design
Current Topics in Medicinal Chemistry Epigenetic Regulation of Myocardial Homeostasis, Self-Regeneration and Senescence
Current Drug Targets Mannose Binding Lectin: A Potential Biomarker for Many Human Diseases
Current Medicinal Chemistry Improved Immunotoxins with Novel Functional Elements
Current Pharmaceutical Design Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Protective Effects of Corticosteroids and Neurosteroids on Cochlear injury
Medicinal Chemistry Targeting Myocardial Metabolism for the Treatment of Stable Angina
Current Pharmaceutical Design Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology Reversal in Cognition Impairments, Cholinergic Dysfunction, and Cerebral Oxidative Stress Through the Modulation of Ryanodine Receptors (RyRs) and Cysteinyl Leukotriene-1 (CysLT1) Receptors
Current Neurovascular Research Cerebrovascular Endothelin Receptor Upregulation in Cerebral Ischemia
Current Vascular Pharmacology Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry The Role of Oxidative Stress in Huntington’s Disease: Are Antioxidants Good Therapeutic Candidates?
Current Drug Targets Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry Current Issues with Glycoprotein IIb-IIIa Antagonists
Current Drug Targets